During Q2 2018 the big money sentiment increased to 1.2. That’s change of 0.20, from 2018Q1’s 1. 31 investors sold all, 169 reduced holdings as Alexion Pharmaceuticals, Inc. ratio is positive. 178 rose stakes while 62 funds bought stakes. Funds hold 203.64 million shares thus 1.34% more from 2018Q1’s 200.94 million shares.
117,552 were accumulated by Thornburg Inv Inc. Stephens Inv Grp Ltd Liability Com holds 20,714 shs. Moreover, Elk Creek Ptnrs has 0.03% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 4,579 shs. Moreover, Great Point Prtnrs has 1.9% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 110,506 shs. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0.07% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Stifel Financial stated it has 61,532 shs. Asset Management One Limited reported 356,339 shs. Sumitomo Mitsui Holdg reported 0.1% stake. Edge Wealth Management Ltd Liability Company holds 0.07% or 2,338 shs. Prudential accumulated 355,278 shs or 0.07% of the stock. D Scott Neal Inc holds 1,200 shs. Marshall Wace Ltd Liability Partnership reported 229,657 shs stake. Fort Washington Invest Advsrs Oh reported 4,410 shs. Rhenman Prtn Asset Mngmt Ab reported 191,863 shs. Zeke Cap Advisors holds 2,429 shs.
Alexion Pharmaceuticals, Inc. registered $1.53 million net activity with 0 insider buys and 5 insider sales since June 8, 2018. Clancy Paul J sold $687,148 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, July 10. Another trade for 1,862 shs valued at $220,703 was made by LAW ANNE-MARIE on Friday, June 8. On Friday, June 8 ORLOFF JOHN J sold $250,691 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 2,115 shs. Franchini Indrani Lall had sold 1,466 shs worth $173,765.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage
In total 5 analysts cover Alexion Pharmaceuticals (NASDAQ:ALXN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ALXN) has 80% bullish analysts. 7 are the (NASDAQ:ALXN)’s ratings reports on Nov 10, 2018 according to StockzIntelligence Inc. On Thursday, October 25 the firm earned “Buy” rating by Citigroup. On Tuesday, September 25 the rating was maintained by Citigroup with “Buy”. In Tuesday, June 5 report Credit Suisse maintained it with “Outperform” rating and $154 target. On Thursday, October 11 the stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Overweight” rating given by Morgan Stanley. On Friday, July 27 JP Morgan maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating. JP Morgan has “Overweight” rating and $188 target. On Tuesday, September 25 the rating was maintained by Stifel Nicolaus with “Hold”. On Tuesday, August 7 the stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Hold” rating by Stifel Nicolaus. Listed here are Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) PTs and latest ratings.
25/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $190 Maintain
11/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $157 New Target: $165 Maintain
25/09/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $173 New Target: $195 Maintain
25/09/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $130 New Target: $136 Maintain
07/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Old Target: $154 New Target: $130 Downgrade
27/07/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $184 New Target: $188 Maintain
05/06/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $149 New Target: $154 Maintain
The stock decreased 2.94% or $3.74 during the last trading session, hitting $123.44.Currently Alexion Pharmaceuticals, Inc. is downtrending after 17.95% change in last November 10, 2017. ALXN has also 1.34M shares volume. ALXN underperformed by 33.57% the S&P500.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products.The firm is worth $27.54 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease.Last it reported negative earnings. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.
For more Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Bioworld.com or Streetinsider.com. The titles are as follows: “Alexion completes acquisition of Syntimmune” released on November 02, 2018, “Alexion Pharmaceuticals beats by $0.28, beats on revenue” on October 24, 2018, “Alexion up 4% premarket on Dicerna deal” with a publish date: October 24, 2018, “Midterm election results bring investors back to biopharma” and the last “Alexion Pharma (ALXN) Announces Upcoming Data Presentations at ASH” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.